Back to Journals » OncoTargets and Therapy » Volume 10

Therapeutic value of 3-D printing template-assisted 125I-seed implantation in the treatment of malignant liver tumors

Authors Han T, Yang X, Xu Y, Zheng Z, Yan Y, Wang N

Received 9 February 2017

Accepted for publication 26 May 2017

Published 3 July 2017 Volume 2017:10 Pages 3277—3283

DOI https://doi.org/10.2147/OTT.S134290

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Dr Carlos Vigil Gonzales

Tao Han,1,* Xiaodan Yang,1,* Ying Xu,2,* Zhendong Zheng,1,* Ying Yan,2 Ning Wang2

1Department of Oncology, 2Department of Radiotherapy, General Hospital of Shenyang Military Region, Shenyang, China

*These authors contributed equally to this work

Objective: To explore the therapeutic value of 3-D printing template-assisted 125I-seed implantation in the treatment of malignant liver tumors.
Materials and methods: Fifteen liver cancer patients with 47 total lesions were treated with 3-D printing template-assisted radioactive seed implantation (group A), and 25 liver-tumor patients with 66 total lesions were treated with 125I-seed implantation without a template auxiliary (group B). Operation time, in-hospital time, operation complications, dose distribution, and response rate (number) were compared between the two groups.
Results: Shorter operation times and better dose distribution were observed in group A than in group B, and the differences were statistically significant. The response rate after 2 months was 86.7% (13 of 15) in group A and 84% (21 of 25) in group B; differences between the two groups were not significant.
Conclusion: Application of 3-D printing template-assisted radioactive seed implantation in the treatment of malignant liver tumors can help shorten operation time and optimize radiation-dose distribution, is worthy of further study, and has clinical significance.

Keywords: brachytherapy, stereotactic techniques, iodine isotopes, liver, carcinoma
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]